SEC Tracker
Get the app

Editas Medicine EDIT

Editas Medicine, Inc. disclosed that it had preliminary unaudited cash, cash equivalents

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Reports quarterly results (2.02)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Editas Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Merus MRUS
  2. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  3. Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
  4. Rezolute RZLT public float $204M, Dec 31, 2025
  5. Cardiff Oncology CRDF public float $205M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.